Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17% - Eli Lilly (NYSE:LLY)
Published on March 19, 2026.
Eli Lilly (NYSE:LLY) has announced that its experimental drug, Retatrutide, has resulted in a 17% weight loss rate over 40 weeks in the TRANSCEND-T2D-1 trial, with participants losing an average of 36.6 lbs (16.8%), and no plateau in weight loss was observed throughout the trial. The trial, which began in 2024, enrolled over 2,050 participants and is part of a larger Phase 3 clinical program assessing retatrutic's efficacy for treating type 2 diabetes. The results are expected to be presented at the American Diabetes Association Scientific Sessions in June.
Related Articles
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The FDA approved a higher dose of Novo Nordisk's weight loss drug Wegovy to compete with Lilly's Zepbound, which has proven more effective in reducing obesity.
Eli Lilly's new shot shows solid weight loss in study — plus, a way for Nvidia to perk up
Eli Lilly's new diabetes treatment retatrutide shows superior weight loss, while oil prices hit $119 per barrel and health-care stocks languishing.
UK to Dissolve Crypto Exchange Accused of Aiding Iranian Sanctions Evasion
The UK has dissolved Zedxion Exchange Ltd, accused of facilitating Iranian sanctions, due to its alleged involvement in facilitating such transactions.